Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
Skye Bioscience Reports Topline CBeyond(TM) Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.